Dear readers of ADxS.org, please forgive the disruption.

ADxS.org needs about $36850 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 18,000 times a week, but only 40 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$27450 of $36850 - as of 2023-11-30
74%
ADxS.org Logo
ADxS.org Logo
Search Sitemap Donations Last Changes Deutsche Version
Register

Existing Account? Login

Header Image
Mirtazapine for ADHD

Sitemap

The ADxS.org project
Abstract of ADxS.org
Symptoms
Consequences
Origin
Stress
Neurological aspects
Diagnostics
Prevention
Treatment and therapy
Medication for ADHD - Overview
Suitable medication for ADHD
Experimental drugs for ADHD
Sleep disorder-related medications for ADHD
Appetite stimulating drugs for ADHD
ADHD drugs in development
Less appropriate medication for ADHD
Vitamins, minerals, dietary supplements for ADHD
Plant extracts for ADHD
Medication and drugs - the difference
Substance abuse with self-medication effects in ADHD.
This and That about ADHD
Tests and surveys
Forum

Mirtazapine for ADHD

Previous Page Next Page

Brand name: Remergil

Dopaminergic, adrenergic, and noradrenergic but not serotonergic antidepressant.

Increases the release of dopamine in the PFC and noradrenergic transmission in cortical-limbic areas.1

Serotonin levels are only marginally affected.1

After 21 days of mirtazapine treatment, rats showed desensitization of presynaptic a2 heteroreceptors at the 5-HT nerve terminal in the hippocampus. This caused increased tonic activation of postsynaptic 5-HT1A receptors.2 This increased tonic activation of inhibitory 5-HT1A receptors could explain the increased CRH release in the HPA axis, which was acutely reduced before treatment initiation.3

  1. Millan, Gobert, Rivet, Adhumeau-Auclair, Cussac, Newman-Tancredi, Dekeyne, Nicolas, Lejeune (2000): Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2-adrenergic and serotonin2C receptors: a comparison with citalopram; DOI: 10.1046/j.1460-9568.2000.00982.x ↥ ↥

  2. Haddjeri, Blier, de Montigny (1998): Long-Term Antidepressant Treatments Result in a Tonic Activation of Forebrain 5-HT1A Receptors; Journal of Neuroscience 1 December 1998, 18 (23) 10150-10156; DOI: https://doi.org/10.1523/JNEUROSCI.18-23-10150.1998 ↥

  3. Büchs (2009): Einfluss von Mirtazapin auf die Hypothalamus-Hypophysen-Nebennierenrindenachse bei depressiven Patienten; Dissertation, Seite 129 ↥

Diese Seite wurde am 13.03.2023 zuletzt aktualisiert.
Previous Page Next Page